Gilead Sciences, Inc. $GILD Stock Holdings Lessened by Jacobs Levy Equity Management Inc.

Key Points

• Jacobs Levy Equity Management Inc. significantly reduced its stake in Gilead Sciences by 81.1%, now holding 122,374 shares worth approximately $13.7 million after selling over 526,000 shares.
• Gilead reported earnings of $2.01 EPS for the quarter, exceeding analysts' estimates, with revenues of $7.08 billion and a year-over-year revenue increase of 1.4%.
• The company announced a quarterly dividend of $0.79 per share, set to be paid on September 29th, reflecting an annualized yield of 2.7%.

Jacobs Levy Equity Management Inc. lowered its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 81.1% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 122,374 shares of the biopharmaceutical company's stock after selling 526,012 shares during the period. Jacobs Levy Equity Management Inc.'s holdings in Gilead Sciences were worth $13,712,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of the stock. Smallwood Wealth Investment Management LLC purchased a new position in shares of Gilead Sciences in the 1st quarter valued at $25,000. Activest Wealth Management raised its stake in shares of Gilead Sciences by 2,837.5% in the 1st quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company's stock valued at $26,000 after acquiring an additional 227 shares during the period. Goodman Advisory Group LLC purchased a new position in shares of Gilead Sciences in the 1st quarter valued at $29,000. Colonial Trust Advisors raised its stake in shares of Gilead Sciences by 304.3% in the 1st quarter. Colonial Trust Advisors now owns 283 shares of the biopharmaceutical company's stock valued at $32,000 after acquiring an additional 213 shares during the period. Finally, Core Alternative Capital raised its stake in shares of Gilead Sciences by 370.8% in the 1st quarter. Core Alternative Capital now owns 306 shares of the biopharmaceutical company's stock valued at $34,000 after acquiring an additional 241 shares during the period. Hedge funds and other institutional investors own 83.67% of the company's stock.

Gilead Sciences Stock Down 1.3%

NASDAQ GILD traded down $1.50 during trading hours on Friday, reaching $116.36. 1,633,794 shares of the company traded hands, compared to its average volume of 8,081,841. Gilead Sciences, Inc. has a 12 month low of $81.57 and a 12 month high of $121.83. The company has a current ratio of 1.32, a quick ratio of 1.15 and a debt-to-equity ratio of 1.13. The stock has a market capitalization of $144.38 billion, a PE ratio of 23.18, a PEG ratio of 0.78 and a beta of 0.36. The company has a 50 day moving average of $113.97 and a two-hundred day moving average of $110.07.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported $2.01 EPS for the quarter, beating analysts' consensus estimates of $1.96 by $0.05. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The firm had revenue of $7.08 billion for the quarter, compared to the consensus estimate of $6.95 billion. During the same period in the prior year, the firm posted $2.01 EPS. The firm's revenue was up 1.4% compared to the same quarter last year. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. As a group, equities analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, September 29th. Shareholders of record on Monday, September 15th will be paid a dividend of $0.79 per share. This represents a $3.16 dividend on an annualized basis and a yield of 2.7%. The ex-dividend date is Monday, September 15th. Gilead Sciences's dividend payout ratio is 62.95%.

Insider Activity at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 2,500 shares of the firm's stock in a transaction dated Friday, August 15th. The shares were sold at an average price of $118.53, for a total value of $296,325.00. Following the transaction, the chief financial officer directly owned 160,110 shares in the company, valued at approximately $18,977,838.30. This trade represents a 1.54% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Johanna Mercier sold 28,000 shares of the firm's stock in a transaction dated Friday, August 15th. The stock was sold at an average price of $118.53, for a total transaction of $3,318,840.00. Following the completion of the transaction, the insider owned 114,168 shares in the company, valued at approximately $13,532,333.04. The trade was a 19.70% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 82,000 shares of company stock valued at $9,371,330. 0.27% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the stock. Royal Bank Of Canada raised their target price on shares of Gilead Sciences from $96.00 to $98.00 and gave the company a "sector perform" rating in a research note on Friday, August 8th. Needham & Company LLC raised shares of Gilead Sciences from a "hold" rating to a "buy" rating and set a $133.00 target price on the stock in a research note on Friday, July 25th. Dbs Bank raised shares of Gilead Sciences to a "moderate buy" rating in a research note on Friday, September 5th. Truist Financial raised shares of Gilead Sciences from a "hold" rating to a "buy" rating and raised their price target for the company from $108.00 to $127.00 in a report on Friday, August 8th. Finally, UBS Group raised their price target on shares of Gilead Sciences from $108.00 to $112.00 and gave the company a "neutral" rating in a report on Friday, August 8th. Three investment analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat, Gilead Sciences currently has a consensus rating of "Moderate Buy" and a consensus target price of $115.39.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.